0RRB Stock Chart & Stats
CHF11.00
-CHF0.09(-0.85%)
At close: 4:00 PM EDT
CHF11.00
-CHF0.09(-0.85%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF11.21
Previous CloseN/A
Volume26.13K
Average Volume (3M)136.78K
Market Cap
CHF493.20M
Enterprise ValueCHF604.15
Total Cash (Recent Filing)CHF89.80M
Total Debt (Recent Filing)CHF265.68M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Mar 18, 2027EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)-1.58
Shares Outstanding54,000,000
10 Day Avg. Volume86,775
30 Day Avg. Volume136,779
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF11.27Price Target Upside2.45% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.72
Revenue Forecast (FY)CHF1.26B
Bulls Say, Bears Say
Bulls Say
Accelerating Prescription And Digital GrowthStrong prescription adoption, expanding digital services and a growing customer base can deepen scale and lifetime value. The shift toward electronic prescriptions and digital care may support more durable retention and cross-selling.
Clear Path Toward Operating BreakevenTightened guidance and a defined breakeven roadmap indicate improving operating leverage. If revenue growth continues while costs are controlled, the company could reduce funding dependence and establish a more sustainable financial model.
Structural Cost And Margin Improvement InitiativesRecurring AI-led savings, lower marketing intensity and improved expense ratios can strengthen margins beyond temporary cuts. These initiatives provide a structural opportunity to convert scale and automation into better profitability.
Bears Say
Persistent Losses And Weak ProfitabilityContinued losses and volatile earnings reduce confidence in the business model’s current economics. Until scale benefits consistently exceed fulfillment, marketing and operating costs, profitability remains a significant execution risk.
Ongoing Cash Burn And Rising Net DebtNegative cash generation limits financial flexibility and may require additional funding if breakeven is delayed. Higher net debt increases financing sensitivity while the company remains dependent on successful operational improvement.
Regulatory, Reimbursement And Co-payment PressureChanges to pharmacy remuneration, discounts and patient co-payments could pressure demand, pricing and prescription economics. Greater price sensitivity may limit margins and complicate growth as the Rx mix expands.
DocMorris News
0RRB FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest share price was CHF3.92 and its highest was CHF11.21 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF493.20M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Mar 18, 2027 which is in 183 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Aug 19, 2026. The company reported -CHF1.1 earnings per share for the quarter.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG pays a Notavailable dividend of CHF0.285 which represents an annual dividend yield of 0.22%. See more information on DocMorris AG dividends here
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -0.59.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 54,000,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -CHF1.1 in its last earnings report. Following the earnings report the stock price went down -1.237%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in GB:0RRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
0RRB Stock 12 Month Forecast
Average Price Target
CHF11.27
▲(2.45% Upside)